Kentaro Minagawa
Research Subjects
Kentaro Minagawa has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Shin Mineishi
Blood and Marrow Transplant Program, Division of Hematology and Oncology Penn State Cancer Institute Hershey Pennsylvania USA
6 shared publicationsMyles Nickolich
Blood and Marrow Transplant Program, Division of Hematology and Oncology Penn State Cancer Institute Hershey Pennsylvania USA
5 shared publicationsBaldeep Wirk
Department of Medicine, Penn State Cancer Institute, Hershey, USA
4 shared publicationsBrooke Silar
Blood and Marrow Transplant Program, Division of Hematology and Oncology Penn State Cancer Institute Hershey Pennsylvania USA
4 shared publicationsChristopher Ehmann
Blood and Marrow Transplant Program, Division of Hematology and Oncology Penn State Cancer Institute Hershey Pennsylvania USA
4 shared publicationsHiroko Shike
Blood and Marrow Transplant Program, Division of Hematology and Oncology Penn State Cancer Institute Hershey Pennsylvania USA
4 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 2008301
Editorial: The role of RNA regulation in cancer pathogenesis and therapeutic strategies
Post-transcriptional regulation of gene expression is a critical determinant of inflammatory protein production and cancer biology. Although transcription initiates cellular responses, the stability, localization, processing, and translation of RNA ultimately determine the magnitude and duration of protein expression. More than 1,500 RNA-binding proteins (RBPs) participate in these processes, highlighting the complexity of RNA-mediated regulation. Among these, CCCH-type zinc-finger proteins-including tristetraprolin 1,2 , Roquin 3 , and the Regnase family 4,5 -play important roles in controlling inflammatory and immune responses.Inflammatory cytokine mRNAs are often intrinsically unstable, allowing rapid induction and subsequent resolution of inflammatory responses. Regulatory sequences within the 3Ⲡuntranslated regions, including AU-rich elements, microRNA-binding sites, and stem-loop structures, provide recognition sites for RBPs and RNA-silencing machinery. Through these mechanisms, inflammatory transcripts such as IL-6, TNF-Îą, IL-2, and IL-17A can be rapidly degraded, or their translation modulated. This post-transcriptional checkpoint is essential for preventing excessive or persistent inflammation. TFL (ZC3H12D/Regnase-4/MCPIP-4), a member of the ZC3H12 family, contains a CCCH-type zinc-finger domain involved in RNA recognition and a PIN-like RNase domain involved in RNA degradation 6 . Although it shares structural and functional features with Regnase-1 (ZC3H12A), the Regnase family members have distinct expression patterns and RNA targets 7 . TFL regulates inflammatory transcripts and appears to function as a negative regulator of immune activation. Its localization to P-body-associated RNA granules further suggests that it participates in dynamic networks controlling RNA storage, degradation, and translation.The immunological significance of TFL is particularly evident in chronic inflammation and autoimmunity. Experimental autoimmune encephalomyelitis demonstrates that loss of TFL can enhance inflammatory responses and pathogenic Th17-cell accumulation, suggesting an important role in controlling persistent inflammation and disease resolution 8 . Regulation of TFL by transcription factors such as BHLHE40 may further connect RNA metabolism with inflammatory T-cell programs. Because BHLHE40-positive and GM-CSF-producing T cells are implicated in graft-versus-host disease (GVHD) 9 , TFL represents a potentially important but still incompletely characterized regulator of GVHD. Direct experimental evidence, however, is needed to establish this connection. TFL also influences cancer biology. Reduced TFL expression has been associated with lymphoma and other malignancies, while experimental loss of TFL can enhance cellular proliferation, NF-ÎşB signaling, inflammatory cytokine production, and tumor-associated inflammation 5,10 . These observations suggest that TFL may function not simply as a tumor suppressor within malignant cells but also as a regulator of the tumor microenvironment and systemic inflammatory consequences of cancer. Its potential effects on NK cells and other immune populations further raise the possibility that RNA-regulatory pathways may influence antitumor immunity.Interestingly, RNA-regulatory proteins are not limited to their function within RNA deregulation.TFL was even found on the cell surface as a receptor for extracellular mRNA, including IL-1β.Tumor stimulation alters the localization of TFL in immune cells. In a mouse model, TFL is present on the cell surface, whereas tumor exposure causes TFL to rapidly move into the intracellular compartment within a few hours 11 , contributing to enhanced immune activity against cancer.TFL functions as an RNA-binding protein and was reported to bind the 3â˛-UTR of IL-1β mRNA, facilitating its movement into the nucleus. This process was associated with increased antiapoptotic activity, NK-cell mobility, and IFN-Îł production, potentially enhancing NK-cellmediated antitumor and antimetastatic effects. Collectively, these papers illustrate a continuum of RNA regulation extending from chromatin and transcriptional control to RNA processing, mRNA stability, RNA-protein interactions, RNA modification, and translation. These mechanisms are not isolated; rather, they form interconnected regulatory networks that influence tumor proliferation, metastasis, inflammation, immune evasion, and therapeutic resistance.Understanding these networks may provide new opportunities for precision oncology. RNAbinding proteins, non-coding RNAs, RNA modifications, and RNA-processing pathways may serve not only as biomarkers but also as therapeutic targets. In particular, manipulating RNAregulatory pathways could have complementary effects on both malignant cells and the immune microenvironment. Future studies should define the direct RNA targets and context-dependent functions of those RNA regulatory proteins, including TFL and other Regnase families, clarify their roles in autoimmune disease, including GVHD, as well as cancer, and determine whether these pathways can be therapeutically exploited to enhance cancer immunotherapy.As the editorial team, we hope that this Research Topic will stimulate further investigation into the expanding field of RNA regulation and contribute to the development of innovative diagnostic and therapeutic strategies for cancer and inflammatory disease.
- 7 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 2008301
Open AccessEditorial: The role of RNA regulation in cancer pathogenesis and therapeutic strategies
Post-transcriptional regulation of gene expression is a critical determinant of inflammatory protein production and cancer biology. Although transcription initiates cellular responses, the stability, localization, processing, and translation of RNA ultimately determine the magnitude and duration of protein expression. More than 1,500 RNA-binding proteins (RBPs) participate in these processes, highlighting the complexity of RNA-mediated regulation. Among these, CCCH-type zinc-finger proteins-including tristetraprolin 1,2 , Roquin 3 , and the Regnase family 4,5 -play important roles in controlling inflammatory and immune responses.Inflammatory cytokine mRNAs are often intrinsically unstable, allowing rapid induction and subsequent resolution of inflammatory responses. Regulatory sequences within the 3Ⲡuntranslated regions, including AU-rich elements, microRNA-binding sites, and stem-loop structures, provide recognition sites for RBPs and RNA-silencing machinery. Through these mechanisms, inflammatory transcripts such as IL-6, TNF-Îą, IL-2, and IL-17A can be rapidly degraded, or their translation modulated. This post-transcriptional checkpoint is essential for preventing excessive or persistent inflammation. TFL (ZC3H12D/Regnase-4/MCPIP-4), a member of the ZC3H12 family, contains a CCCH-type zinc-finger domain involved in RNA recognition and a PIN-like RNase domain involved in RNA degradation 6 . Although it shares structural and functional features with Regnase-1 (ZC3H12A), the Regnase family members have distinct expression patterns and RNA targets 7 . TFL regulates inflammatory transcripts and appears to function as a negative regulator of immune activation. Its localization to P-body-associated RNA granules further suggests that it participates in dynamic networks controlling RNA storage, degradation, and translation.The immunological significance of TFL is particularly evident in chronic inflammation and autoimmunity. Experimental autoimmune encephalomyelitis demonstrates that loss of TFL can enhance inflammatory responses and pathogenic Th17-cell accumulation, suggesting an important role in controlling persistent inflammation and disease resolution 8 . Regulation of TFL by transcription factors such as BHLHE40 may further connect RNA metabolism with inflammatory T-cell programs. Because BHLHE40-positive and GM-CSF-producing T cells are implicated in graft-versus-host disease (GVHD) 9 , TFL represents a potentially important but still incompletely characterized regulator of GVHD. Direct experimental evidence, however, is needed to establish this connection. TFL also influences cancer biology. Reduced TFL expression has been associated with lymphoma and other malignancies, while experimental loss of TFL can enhance cellular proliferation, NF-ÎşB signaling, inflammatory cytokine production, and tumor-associated inflammation 5,10 . These observations suggest that TFL may function not simply as a tumor suppressor within malignant cells but also as a regulator of the tumor microenvironment and systemic inflammatory consequences of cancer. Its potential effects on NK cells and other immune populations further raise the possibility that RNA-regulatory pathways may influence antitumor immunity.Interestingly, RNA-regulatory proteins are not limited to their function within RNA deregulation.TFL was even found on the cell surface as a receptor for extracellular mRNA, including IL-1β.Tumor stimulation alters the localization of TFL in immune cells. In a mouse model, TFL is present on the cell surface, whereas tumor exposure causes TFL to rapidly move into the intracellular compartment within a few hours 11 , contributing to enhanced immune activity against cancer.TFL functions as an RNA-binding protein and was reported to bind the 3â˛-UTR of IL-1β mRNA, facilitating its movement into the nucleus. This process was associated with increased antiapoptotic activity, NK-cell mobility, and IFN-Îł production, potentially enhancing NK-cellmediated antitumor and antimetastatic effects. Collectively, these papers illustrate a continuum of RNA regulation extending from chromatin and transcriptional control to RNA processing, mRNA stability, RNA-protein interactions, RNA modification, and translation. These mechanisms are not isolated; rather, they form interconnected regulatory networks that influence tumor proliferation, metastasis, inflammation, immune evasion, and therapeutic resistance.Understanding these networks may provide new opportunities for precision oncology. RNAbinding proteins, non-coding RNAs, RNA modifications, and RNA-processing pathways may serve not only as biomarkers but also as therapeutic targets. In particular, manipulating RNAregulatory pathways could have complementary effects on both malignant cells and the immune microenvironment. Future studies should define the direct RNA targets and context-dependent functions of those RNA regulatory proteins, including TFL and other Regnase families, clarify their roles in autoimmune disease, including GVHD, as well as cancer, and determine whether these pathways can be therapeutically exploited to enhance cancer immunotherapy.As the editorial team, we hope that this Research Topic will stimulate further investigation into the expanding field of RNA regulation and contribute to the development of innovative diagnostic and therapeutic strategies for cancer and inflammatory disease.
- Open Access
- 8 March 2026
- Published by MDPI AG in Current Oncology
- Vol. 33  (3) , 154
Analyzing Real-World Infection Risk in Multiple Myeloma Patients Receiving Teclistamab
Background: Teclistamab is an anti-B-cell maturation antigen bispecific antibody used in relapsed, refractory multiple myeloma that induces durable responses but is associated with infectious complications. Real-world data characterizing infection risk remain limited. Methods: We conducted a single-center retrospective cohort study of relapsed/re fractory multiple myeloma patients treated with teclistamab from 1 January 2023 to 20 November 2023. The primary objective was to establish the incidence of infections after initiation of teclistamab. Secondary objectives included infection-related outcomes and identifying potential risk factors for infection. Results: 19 patients received teclistamab with a median age of 72 [IQR: 62â74] years and 73.7% had Karnofsky performance score < 80. A total of 11 (57.9%) patients developed 19 infections, with seven patients having multiple infections. There were five bacteremias, five other bacterial infections, seven respiratory viral infections, and 2 CMV reactivation events. Median time to first infection was 20 days (IQR: 9â87) and median grade of all infections was three (range: 1â5). Of the 19 documented infections, 15 (78.9%) were Grade ⼠3. A total of 10 patients in the infection group and three in the non-infection group discontinued therapy permanently (p = 0.013). Conclusion: In this real-world cohort, infectious complications emerged early and frequently during teclistamab therapy and were a major driver of treatment interruption and permanent discontinuation. The clinical impact of infection extended beyond acute morbidity, often limiting continued access to an otherwise effective therapy in a heavily pretreated population. These findings highlight the need for proactive, individualized infection risk assessment and for standardized, evidence-informed approaches to infection monitoring, prophylaxis, and treatment modification during teclistamab therapy. Larger, multicenter studies will be essential to define strategies that balance infection risk with treatment durability in patients with limited therapeutic alternatives.
- 8 March 2026
- Published by MDPI AG in Current Oncology
- Vol. 33  (3) , 154
Open AccessAnalyzing Real-World Infection Risk in Multiple Myeloma Patients Receiving Teclistamab
Background: Teclistamab is an anti-B-cell maturation antigen bispecific antibody used in relapsed, refractory multiple myeloma that induces durable responses but is associated with infectious complications. Real-world data characterizing infection risk remain limited. Methods: We conducted a single-center retrospective cohort study of relapsed/re fractory multiple myeloma patients treated with teclistamab from 1 January 2023 to 20 November 2023. The primary objective was to establish the incidence of infections after initiation of teclistamab. Secondary objectives included infection-related outcomes and identifying potential risk factors for infection. Results: 19 patients received teclistamab with a median age of 72 [IQR: 62â74] years and 73.7% had Karnofsky performance score < 80. A total of 11 (57.9%) patients developed 19 infections, with seven patients having multiple infections. There were five bacteremias, five other bacterial infections, seven respiratory viral infections, and 2 CMV reactivation events. Median time to first infection was 20 days (IQR: 9â87) and median grade of all infections was three (range: 1â5). Of the 19 documented infections, 15 (78.9%) were Grade ⼠3. A total of 10 patients in the infection group and three in the non-infection group discontinued therapy permanently (p = 0.013). Conclusion: In this real-world cohort, infectious complications emerged early and frequently during teclistamab therapy and were a major driver of treatment interruption and permanent discontinuation. The clinical impact of infection extended beyond acute morbidity, often limiting continued access to an otherwise effective therapy in a heavily pretreated population. These findings highlight the need for proactive, individualized infection risk assessment and for standardized, evidence-informed approaches to infection monitoring, prophylaxis, and treatment modification during teclistamab therapy. Larger, multicenter studies will be essential to define strategies that balance infection risk with treatment durability in patients with limited therapeutic alternatives.
- Open Access
- 18 June 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207  (2) , 515-524
Prior status of graftâversusâhost disease affects donor lymphocyte infusion outcomes in patients with relapsed haematological malignancies after allogeneic stem cell transplantation
Summary: Optimizing the effectiveness of donor lymphocyte infusion (DLI) for relapse after allogeneic stem cell transplantation (alloHSCT) has been challenging. We investigated whether the benefits of achieving full donor chimerism (FDC) and developing graftâversusâhost disease (GVHD) after DLI are affected by a history of GVHD before DLI. We retrospectively analysed 56 patients who received DLI for relapse after alloHSCT at our institute from 2015 to 2022. Among 29 patients without GVHD before DLI, those who achieved FDC after DLI had a significantly higher 1âyear overall survival (OS) compared to those who did not (73.7% vs. 20.0%; p < 0.001). Furthermore, in the same cohort, patients who developed GVHD after DLI showed a tendency towards higher OS compared to those who did not (60.0% vs. 52.6%; p = 0.067). In contrast, in patients with GVHD before DLI, there was no significant difference in OS between patients with or without achieving FDC (64.3% vs. 33.3%, p = 0.226) or developing GVHD (60.0% vs. 53.3%, p = 0.866). Our study showed that achieving FDC or developing GVHD after DLI improved OS, but only in those without a prior history of GVHD. The graftâversusâleukaemia effect may be better exploited in patients without a history of GVHD.
- 18 June 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207  (2) , 515-524
Open AccessPrior status of graftâversusâhost disease affects donor lymphocyte infusion outcomes in patients with relapsed haematological malignancies after allogeneic stem cell transplantation
Summary: Optimizing the effectiveness of donor lymphocyte infusion (DLI) for relapse after allogeneic stem cell transplantation (alloHSCT) has been challenging. We investigated whether the benefits of achieving full donor chimerism (FDC) and developing graftâversusâhost disease (GVHD) after DLI are affected by a history of GVHD before DLI. We retrospectively analysed 56 patients who received DLI for relapse after alloHSCT at our institute from 2015 to 2022. Among 29 patients without GVHD before DLI, those who achieved FDC after DLI had a significantly higher 1âyear overall survival (OS) compared to those who did not (73.7% vs. 20.0%; p < 0.001). Furthermore, in the same cohort, patients who developed GVHD after DLI showed a tendency towards higher OS compared to those who did not (60.0% vs. 52.6%; p = 0.067). In contrast, in patients with GVHD before DLI, there was no significant difference in OS between patients with or without achieving FDC (64.3% vs. 33.3%, p = 0.226) or developing GVHD (60.0% vs. 53.3%, p = 0.866). Our study showed that achieving FDC or developing GVHD after DLI improved OS, but only in those without a prior history of GVHD. The graftâversusâleukaemia effect may be better exploited in patients without a history of GVHD.
- Open Access
Evolution of Allogeneic Stem Cell Transplantation: Main Focus on AML
In recent years, treatments in the field of hematologic malignancies have undergone significant evolution; allogeneic hematopoietic stem cell transplantation (allo-HSCT) has shifted from an âultimateâ therapy to becoming a component of a comprehensive therapeutic strategy for acute myeloid leukemia (AML). Advances in risk stratification (including molecular profiling and measurable residual disease assessment), conditioning regimens, and graft-versus-host disease (GVHD) prophylaxisâsuch as post-transplant cyclophosphamideâhave improved outcomes and expanded donor selection and transplant eligibility. We should not only focus on the transplantation procedure but also consider various therapeutic components, including chemotherapy, targeted therapy (possibly including chimeric antigen receptor T-cell therapy), and post-transplant maintenance therapy, which need to be orchestrated within the broader context of leukemia treatment. In this review, we summarized key developments in allo-HSCT for AML and aim to âdecipherâ each component of transplantation.
Open AccessEvolution of Allogeneic Stem Cell Transplantation: Main Focus on AML
In recent years, treatments in the field of hematologic malignancies have undergone significant evolution; allogeneic hematopoietic stem cell transplantation (allo-HSCT) has shifted from an âultimateâ therapy to becoming a component of a comprehensive therapeutic strategy for acute myeloid leukemia (AML). Advances in risk stratification (including molecular profiling and measurable residual disease assessment), conditioning regimens, and graft-versus-host disease (GVHD) prophylaxisâsuch as post-transplant cyclophosphamideâhave improved outcomes and expanded donor selection and transplant eligibility. We should not only focus on the transplantation procedure but also consider various therapeutic components, including chemotherapy, targeted therapy (possibly including chimeric antigen receptor T-cell therapy), and post-transplant maintenance therapy, which need to be orchestrated within the broader context of leukemia treatment. In this review, we summarized key developments in allo-HSCT for AML and aim to âdecipherâ each component of transplantation.
- Open Access
- 12 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25  (2) , 957
Clofarabine Preconditioning followed by Allogeneic Transplant Using TBI and Post-Transplant Cyclophosphamide for Relapsed Refractory Leukemia
Acute myeloid leukemia patients with induction failure or relapsed refractory disease have minimal chance of achieving remission with subsequent treatments. Several trials have shown the feasibility of clofarabine-based conditioning in allogeneic stem cell transplants (allo-HSCT) for non-remission AML patients. Pre-transplant conditioning with clofarabine followed by reduced-intensity allo-HSCT has also demonstrated a potential benefit in those patients with human leukocyte antigen (HLA)-identical donors, but it is not commonly used in haploidentical and mismatched transplants. In this case report, we describe our experience of seven cases of non-remission AML who received clofarabine preconditioning followed by an allo-HSCT with PTCy. The 2-year overall survival and disease-free survival was 83.3% (95% confidence interval (CI): 27.3â97.9%) and 85.7% (95% CI: 33.4â97.9%). Median days of neutrophil and platelet recovery were 16 (range of 13â23) and 28 (range of 17â75), respectively. The cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) at day 100 and chronic GVHD at 1-year showed 28.6% (95% CI: 8â74.2%) and 28.6% (95% CI: 3â63.9%), respectively. The two-year relapse rate was 14.3% (95% CI: 2.14â66.6%). One-year GVHD-free relapse-free survival (GFRS) at 1-year was 71.4% (95% CI: 25.8â92%). Our patients showed successful outcomes with clofarabine preconditioning to reduce the leukemic burden at the pre-transplant period followed by PTCy to reduce GVHD resulting in lower relapsed rate and better GFRS in these patients.
- 12 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25  (2) , 957
Open AccessClofarabine Preconditioning followed by Allogeneic Transplant Using TBI and Post-Transplant Cyclophosphamide for Relapsed Refractory Leukemia
Acute myeloid leukemia patients with induction failure or relapsed refractory disease have minimal chance of achieving remission with subsequent treatments. Several trials have shown the feasibility of clofarabine-based conditioning in allogeneic stem cell transplants (allo-HSCT) for non-remission AML patients. Pre-transplant conditioning with clofarabine followed by reduced-intensity allo-HSCT has also demonstrated a potential benefit in those patients with human leukocyte antigen (HLA)-identical donors, but it is not commonly used in haploidentical and mismatched transplants. In this case report, we describe our experience of seven cases of non-remission AML who received clofarabine preconditioning followed by an allo-HSCT with PTCy. The 2-year overall survival and disease-free survival was 83.3% (95% confidence interval (CI): 27.3â97.9%) and 85.7% (95% CI: 33.4â97.9%). Median days of neutrophil and platelet recovery were 16 (range of 13â23) and 28 (range of 17â75), respectively. The cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) at day 100 and chronic GVHD at 1-year showed 28.6% (95% CI: 8â74.2%) and 28.6% (95% CI: 3â63.9%), respectively. The two-year relapse rate was 14.3% (95% CI: 2.14â66.6%). One-year GVHD-free relapse-free survival (GFRS) at 1-year was 71.4% (95% CI: 25.8â92%). Our patients showed successful outcomes with clofarabine preconditioning to reduce the leukemic burden at the pre-transplant period followed by PTCy to reduce GVHD resulting in lower relapsed rate and better GFRS in these patients.
- 23 August 2023
- Published by Elsevier in Biochemical Engineering Journal
- Vol. 199
Novel fourth generation-like CARmiR cells release therapeutic miRNA via exosomes and enhance glioblastoma cell killing activity
- 23 August 2023
- Published by Elsevier in Biochemical Engineering Journal
- Vol. 199
Novel fourth generation-like CARmiR cells release therapeutic miRNA via exosomes and enhance glioblastoma cell killing activity
- Open Access
- 26 May 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1197112
Tfl deletion induces extraordinary Cxcl13 secretion and cachexia in VavP-Bcl2 transgenic mice
Statement of significance: Loss of TFL, found in several types of lymphoma, induces excessive CXCL13 secretion through RNA dysregulation contributing to body weight loss and early death in lymphoma model mice. Follicular lymphoma (FL) is associated with overexpressed BCL-2 and other genetic aberrations, including 6q-. We identified a novel gene on 6q25, âTransformed follicular lymphoma (TFL),â from a transformed FL. TFL regulates several cytokines via mRNA degradation, which has been suggested to underlie resolving inflammation. Fluorescence in situ hybridization revealed a deletion of TFL occurred in 13.6% of various B-cell lymphoma samples. We developed VavP-bcl2 transgenic, TFL deficit mice (Bcl2-Tg/Tfl-/-) to seek how TFL affects disease progression in this lymphoma model. While Bcl2-Tg mice developed lymphadenopathy and died around 50 weeks, Bcl2-Tg/Tfl-/- mice lost body weight around 30 weeks and died about 20 weeks earlier than Bcl2-Tg mice. Furthermore, we found a unique B220-IgM+ cell population in the bone marrow of Bcl2-Tg mice. cDNA array in this population revealed that Cxcl13 mRNA in Bcl2-Tg/Tfl-/- mice expressed significantly higher than Bcl2-Tg mice. In addition, bone marrow extracellular fluid and serum showed an extremely high Cxcl13 concentration in Bcl2-Tg/Tfl-/- mice. Among bone marrow cells, the B220-IgM+ fraction was the main producer of Cxcl13 in culture. A reporter assay demonstrated TFL regulates CXCL-13 via induction of 3âUTR mRNA degradation in B lineage cells. These data suggest Tfl regulates Cxcl13 in B220-IgM+ cells in the bone marrow, and a very high concentration of serum Cxcl13 arising from these cells may contribute to early death in lymphoma-bearing mice. Since several reports have suggested the association of CXCL13 expression with lymphoma, these findings provide new insights into cytokine regulation via TFL in lymphoma.
- 26 May 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1197112
Open AccessTfl deletion induces extraordinary Cxcl13 secretion and cachexia in VavP-Bcl2 transgenic mice
Statement of significance: Loss of TFL, found in several types of lymphoma, induces excessive CXCL13 secretion through RNA dysregulation contributing to body weight loss and early death in lymphoma model mice. Follicular lymphoma (FL) is associated with overexpressed BCL-2 and other genetic aberrations, including 6q-. We identified a novel gene on 6q25, âTransformed follicular lymphoma (TFL),â from a transformed FL. TFL regulates several cytokines via mRNA degradation, which has been suggested to underlie resolving inflammation. Fluorescence in situ hybridization revealed a deletion of TFL occurred in 13.6% of various B-cell lymphoma samples. We developed VavP-bcl2 transgenic, TFL deficit mice (Bcl2-Tg/Tfl-/-) to seek how TFL affects disease progression in this lymphoma model. While Bcl2-Tg mice developed lymphadenopathy and died around 50 weeks, Bcl2-Tg/Tfl-/- mice lost body weight around 30 weeks and died about 20 weeks earlier than Bcl2-Tg mice. Furthermore, we found a unique B220-IgM+ cell population in the bone marrow of Bcl2-Tg mice. cDNA array in this population revealed that Cxcl13 mRNA in Bcl2-Tg/Tfl-/- mice expressed significantly higher than Bcl2-Tg mice. In addition, bone marrow extracellular fluid and serum showed an extremely high Cxcl13 concentration in Bcl2-Tg/Tfl-/- mice. Among bone marrow cells, the B220-IgM+ fraction was the main producer of Cxcl13 in culture. A reporter assay demonstrated TFL regulates CXCL-13 via induction of 3âUTR mRNA degradation in B lineage cells. These data suggest Tfl regulates Cxcl13 in B220-IgM+ cells in the bone marrow, and a very high concentration of serum Cxcl13 arising from these cells may contribute to early death in lymphoma-bearing mice. Since several reports have suggested the association of CXCL13 expression with lymphoma, these findings provide new insights into cytokine regulation via TFL in lymphoma.
- 17 December 2022
- Published by Springer Nature in Annals of Hematology
- Vol. 102  (3) , 613-620
Donor HLA mismatch promotes full donor T-cell chimerism in the allogeneic stem cell transplant with reduced-intensity conditioning and post-transplant cyclophosphamide GVHD prophylaxis
Full donor T-cell chimerism (FDTCC) after allogeneic stem cell transplant (allo-SCT) has been associated with improved outcomes in hematologic malignancy. We studied if donor human leukocyte antigen (HLA) mismatch improves achievement of FDTCC because mismatched HLA promotes donor T-cell proliferation where recipient T-cells had been impaired by previous treatment. Patients (N = 138) received allo-SCT with reduced-intensity conditioning (RIC) from 39 HLA mismatched donors (16 unrelated; 23 haploidentical) with post-transplant cyclophosphamide (PTCy) or 99 matched donors (21 siblings; 78 unrelated) with PTCy (N = 18) or non-PTCy (N = 81). Achievement of FDTCC by day 100 was higher with HLA mismatched donors than matched donors (82.1% vs. 27.3%, p < 00,001), which was further improved with 200 cGy total body irradiation (87.9%) or lymphoid (versus myeloid) malignancy (93.8%). Since all mismatched transplants used PTCy, FDTCC was higher with PTCy than non-PTCy (68.4% vs. 25.7%, p < 0.00001), but not in the matched transplant with PTCy (38.9%), negating PTCy as the primary driver. Lymphocyte recovery was delayed with PTCy than without (median on day + 30: 100 vs. 630/ÂľL, p < 0.0001). The benefit of FDTCC was not translated into survival outcomes, especially in myeloid malignancies, possibly due to the insufficient graft-versus-tumor effects from the delayed lymphocyte recovery. Further studies are necessary to improve lymphocyte count recovery in PTCy transplants.
- 17 December 2022
- Published by Springer Nature in Annals of Hematology
- Vol. 102  (3) , 613-620
Donor HLA mismatch promotes full donor T-cell chimerism in the allogeneic stem cell transplant with reduced-intensity conditioning and post-transplant cyclophosphamide GVHD prophylaxis
Full donor T-cell chimerism (FDTCC) after allogeneic stem cell transplant (allo-SCT) has been associated with improved outcomes in hematologic malignancy. We studied if donor human leukocyte antigen (HLA) mismatch improves achievement of FDTCC because mismatched HLA promotes donor T-cell proliferation where recipient T-cells had been impaired by previous treatment. Patients (N = 138) received allo-SCT with reduced-intensity conditioning (RIC) from 39 HLA mismatched donors (16 unrelated; 23 haploidentical) with post-transplant cyclophosphamide (PTCy) or 99 matched donors (21 siblings; 78 unrelated) with PTCy (N = 18) or non-PTCy (N = 81). Achievement of FDTCC by day 100 was higher with HLA mismatched donors than matched donors (82.1% vs. 27.3%, p < 00,001), which was further improved with 200 cGy total body irradiation (87.9%) or lymphoid (versus myeloid) malignancy (93.8%). Since all mismatched transplants used PTCy, FDTCC was higher with PTCy than non-PTCy (68.4% vs. 25.7%, p < 0.00001), but not in the matched transplant with PTCy (38.9%), negating PTCy as the primary driver. Lymphocyte recovery was delayed with PTCy than without (median on day + 30: 100 vs. 630/ÂľL, p < 0.0001). The benefit of FDTCC was not translated into survival outcomes, especially in myeloid malignancies, possibly due to the insufficient graft-versus-tumor effects from the delayed lymphocyte recovery. Further studies are necessary to improve lymphocyte count recovery in PTCy transplants.
- 22 October 2022
- Published by Elsevier in Leukemia Research
- Vol. 123, 106969
Low-dose total body irradiation promotes T-cells donor chimerism in reduced-intensity/non-myeloablative allogeneic stem cell transplant with post-transplant cyclophosphamide
- 22 October 2022
- Published by Elsevier in Leukemia Research
- Vol. 123, 106969
Low-dose total body irradiation promotes T-cells donor chimerism in reduced-intensity/non-myeloablative allogeneic stem cell transplant with post-transplant cyclophosphamide
- 12 September 2022
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 57  (11) , 1743-1745
Non-myeloablative allogeneic stem cell transplant with fludarabine and reduced dose cyclophosphamide in acute myeloid leukemia for older adults with comorbidities
- 12 September 2022
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 57  (11) , 1743-1745
Non-myeloablative allogeneic stem cell transplant with fludarabine and reduced dose cyclophosphamide in acute myeloid leukemia for older adults with comorbidities